Using a Digital Neuro Signature to measure longitudinal individual-level change in Alzheimer’s disease: the Altoida large cohort study

Abstract Conventional neuropsychological assessments for Alzheimer’s disease are burdensome and inaccurate at detecting mild cognitive impairment and predicting Alzheimer’s disease risk. Altoida’s Digital Neuro Signature (DNS), a longitudinal cognitive test consisting of two active digital biomarker...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Irene B. Meier, Max Buegler, Robbert Harms, Azizi Seixas, Arzu Çöltekin, Ioannis Tarnanas
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Computer applications to medicine. Medical informatics R858-859.7
Acceso en línea:	https://doaj.org/article/8ad6563ddcef480eb7e920b165677cf6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8ad6563ddcef480eb7e920b165677cf6
record_format	dspace
spelling	oai:doaj.org-article:8ad6563ddcef480eb7e920b165677cf62021-12-02T16:07:04ZUsing a Digital Neuro Signature to measure longitudinal individual-level change in Alzheimer’s disease: the Altoida large cohort study10.1038/s41746-021-00470-z2398-6352https://doaj.org/article/8ad6563ddcef480eb7e920b165677cf62021-06-01T00:00:00Zhttps://doi.org/10.1038/s41746-021-00470-zhttps://doaj.org/toc/2398-6352Abstract Conventional neuropsychological assessments for Alzheimer’s disease are burdensome and inaccurate at detecting mild cognitive impairment and predicting Alzheimer’s disease risk. Altoida’s Digital Neuro Signature (DNS), a longitudinal cognitive test consisting of two active digital biomarker metrics, alleviates these limitations. By comparison to conventional neuropsychological assessments, DNS results in faster evaluations (10 min vs 45–120 min), and generates higher test-retest in intraindividual assessment, as well as higher accuracy at detecting abnormal cognition. This study comparatively evaluates the performance of Altoida’s DNS and conventional neuropsychological assessments in intraindividual assessments of cognition and function by means of two semi-naturalistic observational experiments with 525 participants in laboratory and clinical settings. The results show that DNS is consistently more sensitive than conventional neuropsychological assessments at capturing longitudinal individual-level change, both with respect to intraindividual variability and dispersion (intraindividual variability across multiple tests), across three participant groups: healthy controls, mild cognitive impairment, and Alzheimer’s disease. Dispersion differences between DNS and conventional neuropsychological assessments were more pronounced with more advanced disease stages, and DNS-intraindividual variability was able to predict conversion from mild cognitive impairment to Alzheimer’s disease. These findings are instrumental for patient monitoring and management, remote clinical trial assessment, and timely interventions, and will hopefully contribute to a better understanding of Alzheimer’s disease.Irene B. MeierMax BueglerRobbert HarmsAzizi SeixasArzu ÇöltekinIoannis TarnanasNature PortfolioarticleComputer applications to medicine. Medical informaticsR858-859.7ENnpj Digital Medicine, Vol 4, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Computer applications to medicine. Medical informatics R858-859.7
spellingShingle	Computer applications to medicine. Medical informatics R858-859.7 Irene B. Meier Max Buegler Robbert Harms Azizi Seixas Arzu Çöltekin Ioannis Tarnanas Using a Digital Neuro Signature to measure longitudinal individual-level change in Alzheimer’s disease: the Altoida large cohort study
description	Abstract Conventional neuropsychological assessments for Alzheimer’s disease are burdensome and inaccurate at detecting mild cognitive impairment and predicting Alzheimer’s disease risk. Altoida’s Digital Neuro Signature (DNS), a longitudinal cognitive test consisting of two active digital biomarker metrics, alleviates these limitations. By comparison to conventional neuropsychological assessments, DNS results in faster evaluations (10 min vs 45–120 min), and generates higher test-retest in intraindividual assessment, as well as higher accuracy at detecting abnormal cognition. This study comparatively evaluates the performance of Altoida’s DNS and conventional neuropsychological assessments in intraindividual assessments of cognition and function by means of two semi-naturalistic observational experiments with 525 participants in laboratory and clinical settings. The results show that DNS is consistently more sensitive than conventional neuropsychological assessments at capturing longitudinal individual-level change, both with respect to intraindividual variability and dispersion (intraindividual variability across multiple tests), across three participant groups: healthy controls, mild cognitive impairment, and Alzheimer’s disease. Dispersion differences between DNS and conventional neuropsychological assessments were more pronounced with more advanced disease stages, and DNS-intraindividual variability was able to predict conversion from mild cognitive impairment to Alzheimer’s disease. These findings are instrumental for patient monitoring and management, remote clinical trial assessment, and timely interventions, and will hopefully contribute to a better understanding of Alzheimer’s disease.
format	article
author	Irene B. Meier Max Buegler Robbert Harms Azizi Seixas Arzu Çöltekin Ioannis Tarnanas
author_facet	Irene B. Meier Max Buegler Robbert Harms Azizi Seixas Arzu Çöltekin Ioannis Tarnanas
author_sort	Irene B. Meier
title	Using a Digital Neuro Signature to measure longitudinal individual-level change in Alzheimer’s disease: the Altoida large cohort study
title_short	Using a Digital Neuro Signature to measure longitudinal individual-level change in Alzheimer’s disease: the Altoida large cohort study
title_full	Using a Digital Neuro Signature to measure longitudinal individual-level change in Alzheimer’s disease: the Altoida large cohort study
title_fullStr	Using a Digital Neuro Signature to measure longitudinal individual-level change in Alzheimer’s disease: the Altoida large cohort study
title_full_unstemmed	Using a Digital Neuro Signature to measure longitudinal individual-level change in Alzheimer’s disease: the Altoida large cohort study
title_sort	using a digital neuro signature to measure longitudinal individual-level change in alzheimer’s disease: the altoida large cohort study
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/8ad6563ddcef480eb7e920b165677cf6
work_keys_str_mv	AT irenebmeier usingadigitalneurosignaturetomeasurelongitudinalindividuallevelchangeinalzheimersdiseasethealtoidalargecohortstudy AT maxbuegler usingadigitalneurosignaturetomeasurelongitudinalindividuallevelchangeinalzheimersdiseasethealtoidalargecohortstudy AT robbertharms usingadigitalneurosignaturetomeasurelongitudinalindividuallevelchangeinalzheimersdiseasethealtoidalargecohortstudy AT aziziseixas usingadigitalneurosignaturetomeasurelongitudinalindividuallevelchangeinalzheimersdiseasethealtoidalargecohortstudy AT arzucoltekin usingadigitalneurosignaturetomeasurelongitudinalindividuallevelchangeinalzheimersdiseasethealtoidalargecohortstudy AT ioannistarnanas usingadigitalneurosignaturetomeasurelongitudinalindividuallevelchangeinalzheimersdiseasethealtoidalargecohortstudy
_version_	1718384789046689792

Using a Digital Neuro Signature to measure longitudinal individual-level change in Alzheimer’s disease: the Altoida large cohort study

Ejemplares similares